Abstract
Understanding the mechanisms by which amyloid fibrils are formed, both in vivo and in vitro, is vital for developing methods to treat and prevent debilitating deposition diseases such as Alzheimers disease, Parkinsonas disease, type II diabetes and systemic amyloidoses. In recent years, computer modelling and biophysical studies have broadened our understanding of the biochemical mechanisms underpinning protein aggregation. As a result, it is now believed that the ability to form fibrils is an intrinsic property of polypeptide chains and not isolated to disease-related proteins or peptides. Molecular chaperones are a diverse group of functionally related proteins well known for their ability to suppress amyloid formation, and are likely to be important determinants in deciding the fate of protein aggregation prone proteins in vivo. Evidence is presented that suggests that there is striking commonality in the anti-amyloidogenic activity of molecular chaperones regardless of their structural and spatial differences. In this review, we focus on what in vitro biophysical studies tell us about amyloid formation and molecular chaperones, and how investigating the role of chaperones in fibril formation can enhance our understanding of protein misfolding diseases.
Keywords: Amyloid, protein deposition disease, chaperone, oligomer, aggregation
Current Chemical Biology
Title: Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease
Volume: 4 Issue: 2
Author(s): Justin J. Yerbury and Janet R. Kumita
Affiliation:
Keywords: Amyloid, protein deposition disease, chaperone, oligomer, aggregation
Abstract: Understanding the mechanisms by which amyloid fibrils are formed, both in vivo and in vitro, is vital for developing methods to treat and prevent debilitating deposition diseases such as Alzheimers disease, Parkinsonas disease, type II diabetes and systemic amyloidoses. In recent years, computer modelling and biophysical studies have broadened our understanding of the biochemical mechanisms underpinning protein aggregation. As a result, it is now believed that the ability to form fibrils is an intrinsic property of polypeptide chains and not isolated to disease-related proteins or peptides. Molecular chaperones are a diverse group of functionally related proteins well known for their ability to suppress amyloid formation, and are likely to be important determinants in deciding the fate of protein aggregation prone proteins in vivo. Evidence is presented that suggests that there is striking commonality in the anti-amyloidogenic activity of molecular chaperones regardless of their structural and spatial differences. In this review, we focus on what in vitro biophysical studies tell us about amyloid formation and molecular chaperones, and how investigating the role of chaperones in fibril formation can enhance our understanding of protein misfolding diseases.
Export Options
About this article
Cite this article as:
J. Yerbury Justin and R. Kumita Janet, Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease, Current Chemical Biology 2010; 4 (2) . https://dx.doi.org/10.2174/2212796811004020089
DOI https://dx.doi.org/10.2174/2212796811004020089 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Proteomic Analysis of Mitochondrial Complex III Inhibition in SH-SY5Y Human Neuroblastoma Cell Line
Current Proteomics Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Genome-wide Network-assisted Association and Enrichment Study of Amyloid Imaging Phenotype in Alzheimer’s Disease
Current Alzheimer Research Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development
Current Topics in Medicinal Chemistry Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment
CNS & Neurological Disorders - Drug Targets Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Applications of Human Umbilical Cord Blood Cells in Central Nervous System Regeneration
Current Stem Cell Research & Therapy Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Protein Aggregation: Elucidation of the Mechanism and Determination of Associated Thermodynamic and Kinetic Parameters
Current Physical Chemistry Gene Therapy in Peripheral Nerve Reconstruction Approaches
Current Gene Therapy JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of Stem Cells in Amyotrophic Lateral Sclerosis
Current Signal Transduction Therapy Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)